OTC Nexium 24HR Rides Blockbuster History Into Full Field Of Competitors
This article was originally published in The Tan Sheet
Pfizer launches Nexium 24HR, the OTC progeny of AstraZeneca PLC’s prescription drug marketed in the U.S. as “the purple pill,” into the nonprescription PPI market, where other well-known brands and private label versions of some products already compete for share.
You may also be interested in...
Pfizer will pay AstraZeneca $250 million upfront for global rights to market a potential OTC 20-mg Nexium. Pharma marketing expert Joe McGovern expects Nexium “to start OTC with a big bang,” but Center for Consumer Self Care Executive Director Bill Soller points to potential safety questions about a switch.
States’ histories with legalizing cannabis aren’t good models for an hemp regulatory pathway, says FDA hemp and cannabis policy chief Norman Birenbaum. Influence from those models already seen in US with ingredients including delta-8 THC marketed as hemp as defined in federal law de-scheduling it as a controlled substance.
“Something needed to be done” to improve FDA’s regulation of human foods supply, says Commissioner Califf says. “Dietary supplements is a whole different kettle of fish that we can discuss at a later time.”